Real-time FRET assay for monitoring detyrosination by TMCP1 and VASH2

Matthieu Simon1, Julien Espeut2, François Juge2

  • 1IBMM, Université Montpellier, CNRS, ENSCM, Montpellier, France.

Insights

Researchers developed a sensitive FRET assay to measure Tubulin MetalloCarboxyPeptidase 1 (TMCP1) and VASH2 enzyme activity. This tool aids in discovering inhibitors for alpha-tubulin detyrosination, a process linked to cancer and neurodegeneration.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Enzymology

Background:

  • Tubulin detyrosination is a critical posttranslational modification of alpha-tubulin.
  • Dysregulation of tubulin detyrosination is linked to neurodegenerative diseases and cancer.
  • Vasohibin (VASH) family proteins (VASH1, VASH2) were identified as detyrosination enzymes; Tubulin MetalloCarboxyPeptidase 1 (TMCP1) is a newly discovered class.

Purpose of the Study:

  • To develop a sensitive assay for studying the activity of TMCP1 and VASH2.
  • To enable real-time kinetic monitoring of alpha-tubulin detyrosination.
  • To facilitate the discovery of novel inhibitors targeting these enzymes.

Main Methods:

  • Development of a Förster Resonance Energy Transfer (FRET)-based enzymatic assay.
  • Utilized 3-nitrotyrosine as a quencher and a fluorogenic substrate (FS2) mimicking natural tyrosine.
  • Employed enzyme kinetics, competition assays, and metal ion dependency studies.

Main Results:

  • The FRET assay demonstrated high sensitivity, specificity, and robustness.
  • The assay effectively monitors TMCP1 and VASH2 activity in real-time.
  • 3-nitrotyrosine provided efficient quenching and substrate mimicry, enhancing assay performance.

Conclusions:

  • A novel, reliable FRET assay was established for alpha-tubulin detyrosination enzymes TMCP1 and VASH2.
  • This assay is a valuable tool for characterizing enzyme kinetics and identifying potential therapeutic inhibitors.
  • The findings support targeting alpha-tubulin detyrosination for treating relevant disorders.